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Abstract
Background: Germline mutations of the SDHD, SDHB and SDHC genes, encoding three of the
four subunits of succinate dehydrogenase, are a major cause of hereditary paraganglioma and
pheochromocytoma, and demonstrate that these genes are classic tumor suppressors. Succinate
dehydrogenase is a heterotetrameric protein complex and a component of both the Krebs cycle
and the mitochondrial respiratory chain (succinate:ubiquinone oxidoreductase or complex II).
Methods: Using conformation sensitive gel electrophoresis (CSGE) and direct DNA sequencing
to analyse genomic DNA from peripheral blood lymphocytes, here we describe the mutation
analysis of the SDHB and SDHC genes in 37 patients with sporadic (i.e. no known family history)
head and neck paraganglioma and five pheochromocytoma and/or paraganglioma families.
Results: Two sporadic patients were found to have a SDHB splice site mutation in intron 4,
c.423+1G>A, which produces a mis-spliced transcript with a 54 nucleotide deletion, resulting in an
18 amino acid in-frame deletion. A third patient was found to carry the c.214C>T (p.Arg72Cys)
missense mutation in exon 4 of SDHC, which is situated in a highly conserved protein motif that
constitutes the quinone-binding site of the succinate: ubiquinone oxidoreductase (SQR) complex
in E. coli. Together with our previous results, we found 27 germline mutations of SDH genes in 95
cases (28%) of sporadic head and neck paraganglioma. In addition all index patients of five families
showing hereditary pheochromocytoma-paraganglioma were found to carry germline mutations of
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SDHB: four of which were novel, c.343C>T (p.Arg115X), c.141G>A (p.Trp47X), c.281G>A
(p.Arg94Lys), and c.653G>C (p.Trp218Ser), and one reported previously, c.136C>T, p.Arg46X.
Conclusion: In conclusion, these data indicate that germline mutations of SDHB and SDHC play
a minor role in sporadic head and neck paraganglioma and further underline the importance of
germline SDHB mutations in cases of familial pheochromocytoma-paraganglioma.
Background
Paragangliomas (PGL) of the head and neck (also known
as glomus tumors) are parasympathetically innervated,
benign tumors, most commonly arising at the carotid
bifurcation, but also frequently found as vagal and jugulo-
tympanic tumors. Pheochromocytomas are paraganglio-
mas of the sympathetic nervous system, frequently
catecholamine-secreting and arising in the chromaffin
cells of the adrenal medulla. Extra-adrenal paraganglio-
mas (often described as extra-adrenal pheochromocyto-
mas) also originate from the sympathoadrenal
neuroendocrine system and are designated based upon
the primary anatomic site of origin.
Although many cases of head and neck paraganglioma are
apparently sporadic (i.e. no known family history), clus-
tering in families has long been recognized [1,2], and the
search for susceptibility loci led to the mapping of two
putative loci: PGL1-11q23 [2,3] and PGL2-11q13 [4]. The
identification of PGL1 followed in 2000, when Baysal et al
[5] reported germline mutations in SDHD (succinate
dehydrogenase, subunit D) in PGL1-linked families. Sub-
sequently, germline mutations in SDHC (PGL3-1q21) [6]
and SDHB (PGL4-1p36) [7] were identified using a candi-
date gene approach, and both Astuti et al [7] and others
[8-14] have reported that germline mutations of SDHB are
involved in familial pheochromocytoma. It is now known
that SDHB and SDHD, together with VHL and RET, play a
major role in hereditary pheochromocytoma [15].
The three PGL genes identified to date encode subunits of
the heterotetrameric succinate dehydrogenase complex of
the mitochondrial-respiratory chain (complex II) and the
Krebs cycle. While SDHB encodes one of the two subunits
of the catalytic core, the iron-sulfur protein, the SDHC
and SDHD proteins anchor complex II in the inner mito-
chondrial membrane.
Previously we reported the frequency of SDHD mutations
in familial and sporadic head and neck paraganglioma in
the Netherlands [16]. Nearly all clearly familial paragang-
lioma is accounted for by the Dutch founder mutations
Asp92Tyr and Leu139Pro. In addition, about one third of
sporadic cases are also due to one of these mutations.
However, a group of 37 sporadic patients tested negative
for SDHD mutations. Here we report the analysis of the
SDHB and SDHC genes in this group of patients and in
addition the analysis of 5 families presenting with pheo-
chromocytoma and/or paraganglioma.
Methods
Patients
Patients ascertained in the Netherlands were from the Lei-
den University Medical Centre (Leiden, The Netherlands),
the VU Medical Centre (Amsterdam, The Netherlands),
the Utrecht Medical Centre (Utrecht, The Netherlands),
and the University Medical Center Groningen (Gronin-
gen, The Netherlands). Other patients were ascertained
from the Sir Mortimer B Davis-Jewish General Hospital,
Montreal, Canada, the Instituto Nazionale Tumori, Milan,
Italy and the Great Western Hospital, Swindon, UK. The
institutional ethical committee of Leiden University Med-
ical Center approved this study. All patients provided
informed consent. Patients were diagnosed with head and
neck paraganglioma, extra-adrenal paraganglioma or
(adrenal) pheochromocytoma. In this article we subscribe
to the tumor nomenclature described in Lack "Atlas of
tumor pathology, Tumors of the Adrenal Gland and Extra-
Adrenal Paraganglia" [17]. Cases were considered to be
familial when one or more first or second-degree relatives
were diagnosed with a related tumor, either paragangli-
oma or pheochromocytoma. Sporadic cases had no
known family history. All studies were carried out using
genomic DNA isolated from peripheral blood.
Mutation analysis and sequencing
Mutation screening of the SDHB and SDHC genes was
performed with genomic DNA and conformation sensi-
tive gel electrophoresis (CSGE). The 8 exons of SDHB and
the 6 exons of SDHC and at least 15–50 bp of each flank-
ing intron were amplified (primers purchased from
Sigma-Genosys, UK) (primer sequences available on
request). Forward primers were labelled with FAM, HEX,
or TET and amplified in a 10 µl reaction volume with 10
uM primers, 1× Super TAQ buffer (HT Biotechnology,
UK), 0.6 mM dNTPs, and 0.02 U Silverstar Taq polymer-
ase (EuroGentech, Belgium) and 100 ng genomic DNA
sample. PCR was performed for 38 cycles (30 s; 94°C, 30
s; 53–62°C, 30 s; 72°C) with a final extension of 30 min
at 72°C. Reaction mixtures were then pooled in a
HEX:FAM:TET ratio of 3:2:2 and run on a CSGE gel with a
modified gel matrix consisting of 0.5× MDE, 15% forma-
mide in 1× TBE. The samples were run for 5.0 hours at
1680 V at 30°C on an ABI 377 DNA sequencer. Gels wereB
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Table 1: Variants/mutations of SDHB and SDHC with primers, restriction enzymes, PCR restriction products, and allele frequency.
Variant Gene Primersa PCR Product size Enzyme Normal Product Variant Product Alleleb Frequency
Ser8Ser SDHB CGCGGCTAGTGGGTCCTCAG 165 Xho I 140+25 165 4/384
CAAGGGTTGTGGCCGGCAACCGGCGCCTCG
Ala6Ala SDHB CAGTGGATGTAGGCTGGGCGCC 130 Bsr BI 130 110+20 8/260
AACCGGCGCCTCAAGGAGCG
Trp47X SDHB TCCTTCAATAGCTGGCTTTCACAGA 119 Nco I 24 + 95 119 1/314
ATCAAGAAATTTGCCATCTATCCATG
Arg94Lys SDHB GACTCTACTTTGACCTTCCGAAGATCCTGC 167 Pst I 109+33+25 134+33 0/296
TAGGTTGCACAGCAAGTTCAC
Arg115X SDHB ATCAATGGAGGCAACACTCTAGCTTGCAGC 150 Pvu II 150 125+25 0/402
TGCAAATAAAAACAAAACCA
c.423+1G>A SDHB CATGTATGTGATAAAGGATCTTGTTCTC 157 Bsp HI 157 132+25 0/294
TTACTATCTGACTAGAAG
Trp218Ser SDHB AGCTAATCATCCCTGGTTTT 215 Taq I 215 181+34 0/318
TTGTGAGCACATGCTACTTC
Arg72Cys SDHC GCCAATGAAACAGCCAAGTT 163 Dsa I (=Btg I) 49+22+92 49+114 0/328
TTCCTTTTTAAAATTGTCTTTGTGTG
aMismatched nucleotides for the PIRA PCR technique are indicated in bold. bAllele frequency is shown as total chromosomes.BMC Medical Genetics 2006, 7:1 http://www.biomedcentral.com/1471-2350/7/1
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analysed with GeneScan®  and Genotyper®  software
(Applied Biosystems). Each abnormally migrating prod-
uct was reamplified from the DNA sample using the same
primers as above without label and sequenced in the for-
ward direction using standard methods. All the patients
ascertained in Leiden had previously been investigated for
the presence of SDHD mutations using SSCP and restric-
tion digestion analysis and found to be negative.
Mutations in three of the familial pheochromocytoma-
paraganglioma cases were detected using CSGE analysis
and confirmed by direct sequencing, while the remaining
two were identified by direct sequencing of the SDHB
gene, indicated by a suspicious clinical history. Further
family members were identified as carriers using restric-
tion analysis developed by us (Table 1).
Mutations are described in accordance with the recom-
mendations of the Human Genome Variation Society
(HGVS), update August 2004, and it should be noted that
the current nomenclature can differ significantly from pre-
vious versions [18] and from that used in older literature.
PCR screening of controls
Genomic DNA samples of 150–200 (300–400 chromo-
somes) healthy blood donors from the Leiden Blood Bank
were screened for each of the mutations/polymorphisms.
To detect SDHB variants, mismatch PCR primers were
designed and appropriate restriction enzymes were
selected using the PIRA PCR software [19] (Table 1). The
SDHC variant could be detected by loss of a naturally
occurring DsaI restriction site. PCR products were digested
and visualized with ethidium bromide on agarose gels in
the concentration ranges 2.0 to 3.0%
RT-PCR analysis of splicing of SDHB (c.423+1G>A)
RNA was extracted from EBV-transformed PBLs using Tri-
zol (Invitrogen, The Netherlands).
First strand synthesis of cDNA was carried out using 1 µg
RNA, 4 ul of 5 × RT buffer, 5 mM dNTPs, 10 mM DTT, 100
units of MMLV RT and 1 µl of a 1:1 mixture of oligo dT/
random hexamers (500 ng/µl) in 20 µl final volume at
37°C for 1 hour followed by PCR with 2 µl of the above
reaction mixture and a forward primer for SDHB exon 3
(TGACTCTACTTTGACCTTCC) and a reverse primer for
SDHB exon 5 (CTTCCTGAGATTCATCCTTC). The PCR
reaction was as follows: 94°C, 3 min, with 38 cycles
(94°C; 30 sec, 60°C; 30 sec, 72°C; 30 sec) followed by 5
min at 72°C. SDHB RT-PCR products were then analysed
using 3% agarose gel electrophoresis/ethidium bromide
and visualized on a UV illuminator.
Results
Our study can be divided into two groups: 37 cases of spo-
radic head and neck paraganglioma from the Leiden Uni-
versity Medical Center; and 5 index cases with
pheochromocytoma and/or paraganglioma and familial
antecedents, collected from several other national and
international clinical centers.
Of the 37 cases with sporadic head and neck paragangli-
oma, 2 individuals were identified as carrying hetero-
zygous germline mutations of SDHB (5%).
Two patients carried a splice site mutation in intron 4,
c.423+1G>A (Table 2). Patient S-003, a 50 year old male,
presented with elevated catecholamine levels and single
jugular paraganglioma, and died at the age of 58 due to
complications resulting from tumor recurrence. A second
male patient, S-020, presented at the age of 55 with a sin-
gle carotid body tumor which was successfully removed,
and a subsequent MRI scan three years later showed no
abnormalities. This patient was described briefly in a pre-
vious report that examined SDH activity in paragangli-
oma, using the former mutation nomenclature of
IVS4+1G>A [20]. The tumor from this patient was nega-
tive for SDH activity.
The splice site mutation in intron 4 abolishes the consen-
sus splice donor sequence and thus may result in splicing
abnormalities. RNA was available from patient S-020, and
RT-PCR analysis confirmed that splicing was shifted 54
nucleotides upstream of the normal splice site, into the
exon 4 coding sequence, leading to an in frame deletion
of 18 amino acids (Figure 1). Normal control RNA did not
reveal any alternative splicing. This variant was not found
in the control population of 300 chromosomes. This
mutation has recently been identified in two other
patients of Dutch origin. As these patients are all of ethnic
Dutch origin and are apparently unrelated, this mutation
may represent a SDHB founder mutation in The Nether-
lands.
All sporadic patients were also analyzed for mutations in
the six exons of SDHC. A single patient, a 36-year-old
male of Turkish origin, was found to carry a germline
mutation of SDHC. This patient was diagnosed with a sin-
gle carotid body tumor, and had no known family history.
A transition of C to T at base pair 214 in exon 4, resulted
in the missense mutation of a highly conserved arginine
residue (p.Arg72Cys), located in the putative quinone-
binding site of complex II. A C. elegans mutant, mev-1,
(SDHC) that results in oxidative stress and premature age-
ing also affects a residue of the quinone binding site, at
position 69 of the human sequence [21]. This mutation is
only the fifth identified in SDHC to date. The variant was
not found in a Dutch control population of 328 chromo-B
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Table 2: Mutations of SDHB and SDHC found in this study.
Gene Gene Exon-Intron Mutationa Mutation 
(Protein)
Patient ID Country of 
Origin
Age at 
Diagnosis
Sex 
(index case)
Family History Clinical Features
SDHB exon 2 c.136C>T p.Arg46X FGT68 United 
Kingdom
32 Female Sister and father (?) Vagal and jugulotympanic 
paraganglioma
SDHB exon 2 c.141G>A p.Trp47X FGT62 Italy 35 Female Two sisters and paternal aunt, all 
carriers
Metastatic multifocal 
retroperitoneal paraganglioma
SDHB exon 3 c.281G>A p.Arg94Lys FGT57 Pakistan 56 Male Brothers and a nephew 
(proband and nephew tested and 
positive)
Retroperitoneal paraganglioma, 
jugulotympanic paraganglioma, 
adrenal tumor
SDHB exon 4 c.343C>T p.Arg115X FGT61 Netherlands 36 Female Sister and female maternal 
cousin
Bifocal extra-adrenal 
paraganglioma
SDHB intron 4 c.423+1G>
A
Splice Site S-003 Netherlands 50 Male Sporadic Jugulotympanic paraganglioma
SDHB intron 4 c.423+1G>
A
Splice Site S-020 Netherlands 55 Male Unknown Carotid body paraganglioma, 
unilateral
SDHB exon 7 c. 653G>C p.Trp218Ser FGT66 Netherlands 68 Female Daughter with paraganglioma Extra-adrenal paraganglioma left 
para-aortal
SDHC exon 4 c.214C>T p.Arg72Cys S-048 Turkey 36 Male Sporadic Carotid body paraganglioma, 
unilateral
aAll mutations are novel except p.Arg46X. Mutations described in this report follow the recommended nomenclature of the HGVS, update August 2004.BMC Medical Genetics 2006, 7:1 http://www.biomedcentral.com/1471-2350/7/1
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somes (although it should be noted that such a group is
not an appropriate ethnic control to exclude the possibil-
ity of a non-functional Turkish polymorphism).
The functionality of all missense mutations should be
interpreted cautiously, and particularly in a case such as
this as this is only the second report of a missense muta-
tion of SDHC and the patient presented without a family
history.
In none of the sporadic cases was DNA available from the
parents, so we were not able to establish whether these
were de novo mutations.
In addition to the cases with sporadic head and neck par-
aganglioma, 5 index cases with pheochromocytoma and/
or paraganglioma were collected, all of which were known
or subsequently found to have a family history (Table 2).
The first index case, a 36-year-old Dutch female patient
(FGT 61.1) presented with a suspected extra-adrenal para-
ganglioma, and two paragangliomas (close to left kidney)
were identified. After surgical removal no additional clin-
ical signs of paraganglioma could be detected. The sister
of the index patient (FGT61.2) presented at the age of 27
with symptoms of dizziness and elevated noradrenalin.
An extra-adrenal paraganglioma, located between the
pancreas and left kidney was identified. A female cousin
had previously been diagnosed with paraganglioma but
was not available for testing. Both patients were found to
carry a germline nonsense mutation of SDHB, c.343C>T
(p.Arg115X) which leads to a truncation of the protein at
under half its normal length of 280 amino acids.
A second Dutch index patient (FGT66), presented at the
age of 67 (2004) with pain in the upper abdomen, and a
CT-scan revealed a left-sided retroperitoneal mass.
Normetanephrine was highly elevated and were no indi-
cations of localisations or metastases elsewhere. The
patient's daughter had previously been diagnosed with
paraganglioma of the carotid body, that was removed at
the age of 29.
No other family members have clinical signs of either par-
aganglioma or pheochromocytoma. Analysis of DNA
from the index patient revealed a missense mutation c.
653G>C (p.Trp218Ser) in exon 7 of SDHB. This missense
change affects an amino acid that is conserved in both
mammals and in D. melanogaster, C. elegans, S. cerevisiae
and A. thaliana. This variant was not found in 318 chro-
mosomes from healthy blood donors. The daughter of the
index patient was subsequently tested and also carries the
mutation. Other family members are currently receiving
genetic counseling.
A 35-year-old Italian female (FGT62.1) presented with a
family history of retroperitoneal paraganglioma, severe
hypertension, and elevated urinary excretion of catecho-
lamine metabolites. An extra-adrenal paraganglioma,
infiltrating the Glissonian of the liver, was surgically
removed. At follow-up, MIBG scintiscan showed 3 areas
of intense uptake including the site of the previous surgery
and two paravertebral lesions in the abdomen and chest.
It is not known if these were metastases or primary
tumors, as the patient refused further investigation. One
year later the patient was suffering from widespread dis-
ease with bone metastases.
A sister (FGT62.2) of the index case presented at the age of
13 with an abdominal mass below the aortic bifurcation
and increased urinary excretion of catecholamine metab-
olites. At surgery a 10 × 7 cm retroperitoneal paragangli-
oma was removed. At the age of 29, a left-sided cervical
paraganglioma was diagnosed and removed. After two
further relapses the patient presently shows bone metas-
tases and a retroperitoneal mass, possibly a new tumor.
At the age of 60, a paternal aunt (FGT62.3) of the index
case was found to have a paraganglioma of the posterior
mediastinum. The patient had no further symptoms, and
both she and her sons have refused further follow-up.
The index patient was found to carry a c.141G>A germline
variant of SDHB resulting in a stop codon at codon 47
(p.Trp47X). Analysis of the DNA of the sister and aunt
confirmed their carrier status for the mutation and dem-
onstrated that the mutation segregated with disease. Sur-
prisingly, this mutation was also identified in one sample
from the Dutch blood donors screened as controls (1/314
chromosomes). As these donors are anonymous no infor-
mation is available on the clinical status of this individual.
FGT57.6, a male of Pakistani descent, presented with a ret-
roperitoneal paraganglioma, and had three male relatives
(from a large extended family) with similar clinical pro-
files. A preoperative CT scan revealed a retroperitoneal
mass adherent to inferior vena cava and extending up to
the left renal vein. Pathology revealed a 9 × 8 × 4 cm
encapsulated mass. This patient is currently doing well at
age 61.
The brother (FGT57.8) of the index case was first seen at
the age 47 with a paraganglioma arising in the diaphragm.
The patient is currently alive. A second brother (FGT57.9)
presented with adrenal cell carcinoma with bone and lung
metastases. An arteriogram revealed an 11 cm highly vas-
cularised adrenal neoplasm, most likely a primary adre-
nal, with vascular metastases to the left ileum. No
remarkable hormonal changes were found. The patient
died at age 41.BMC Medical Genetics 2006, 7:1 http://www.biomedcentral.com/1471-2350/7/1
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The nephew of the index patient (FGT57.7) presented at
the age of 27 with a recent history of diminished hearing,
pulsatile tinnitus and positional vertigo. A CT scan
revealed a classic glomus jugulare tumour. The patient
completed radiation therapy and remains stable.
The index case and his nephew were available for testing
and both were found to be carrying a missense variant of
SDHB, c.281G>A, resulting in the substitution of arginine
for lysine at codon 94 (p.Arg94Lys). Arginine 94 is highly
conserved and adjacent to a cysteine that constitutes one
of the highly conserved cysteine regions that are the puta-
tive non-heme iron-sulfur clusters of SDHB [22].
Finally, a 32-year-old English woman (FGT68) presented
with neck pain, swelling at the jaw, left vocal cord palsy
and some wasting of the trapezius muscle. An MRI scan
showed a para-pharyngeal mass, most likely a vagal para-
ganglioma. At surgery a highly vascular tumor virtually
encircling the internal carotid artery and intimately con-
nected to the hypoglossal nerve was revealed. A sub-total
resection was carried out but the tumor progressed and
the patient eventually died at the age of 39. The sister of
the index patient underwent surgery for a jugulotympanic
paraganglioma at the age of 33. The father of the index
patient was still alive at the age of 75 and had a vague his-
tory of surgery for lumps on the face and neck. Other
members of the family currently have no symptoms. The
index patient was found to carry a previously described
mutation in exon 2 of SDHB, c.136C>T, p.Arg46X [9]. The
family is currently being offered genetic counseling.
Discussion
Of the sporadic head and neck paraganglioma cases 8%
were found to carry a germline mutation of SDHB or
SDHC. Including our previous results [16], we have
screened a total of 95 sporadic head and neck paragangli-
oma cases for germline mutations of SDH genes and
found 24 (25%) in SDHD, 2 (2%) in SDHB and 1 (1%)
in SDHC (total = 28%). Further studies will be required to
discern whether the remaining cases can be explained by
mutations of SDH genes not currently detectable with the
techniques used or whether these are true sporadic cases,
not attributable to germline mutations of one of the SDH
genes.
In light of the known role of founder mutations in Dutch
PGL cases [16], it seems likely that the majority of appar-
ently 'sporadic' cases are related to other patients carrying
the same mutation, rather than being true sporadic cases
carrying  de novo somatic or germline mutations. This
seems particularly likely in the case of the very common
SDHD mutation Asp92Tyr (D92Y) which accounts for 19
of the 24 sporadic SDHD cases, but may also explain the
prevalence of the c.423+1G>A SDHB mutation.
Previous studies of mutations of SDH genes related to
sporadic head and neck paraganglioma have examined
SDHB, C, and D together [8,23-25] or SDHD only
[16,26]. The four studies examining all three genes
included 103 cases and found 3 mutations of SDHB, 0
mutations of SDHC and 7 mutations of SDHD. Including
the current study, a total of 5 mutations of SDHB have
been found in 141 cases (3.5%), and 1 of SDHC (0.7%).
The two studies that looked only at SDHD were both con-
ducted in The Netherlands and found 33 mutations in 93
Dutch cases (35%). The higher incidence in The Nether-
lands is largely attributable to the common Dutch muta-
tions Asp92Tyr (D92Y), Leu95Pro (L95P) and Leu139Pro
(L139P).
While this study was conducted with the aim of identify-
ing the incidence of germline mutations of SDHB and
SDHC in paraganglioma/pheochromocytoma, it is worth
remembering that we did not examine DNA from tumors,
so no conclusion can be drawn on the incidence of
somatic mutations of SDHB and SDHC in paraganglioma.
Previous studies that did address this question, including
SDHD, [7-9,25-30] found no evidence of somatic SDH
mutations playing a role in paraganglioma, with the
exception of Gimm et al [31] who reported a single case
with a somatic mutation of SDHD, Pro81Leu. This muta-
tion has since been commonly reported in germline sam-
ples of individuals of Northern European origin, but has
never again been found only in tumor DNA.
The SDHB mutation c.423+1G>A disrupts normal splicing Figure 1
The SDHB mutation c.423+1G>A disrupts normal 
splicing. Primers in exon 3 and exon 5 were used to amplify 
cDNA. Lane 1: Patient S-020: In addition to a product of 
~250 bp, a fragment missing 54 bp was also amplified 
(arrow). Sequencing showed an SDHB cDNA missing the 
proximal portion of exon 4. Lanes 2–4: RNA from three 
healthy controls included in the analysis revealed no addi-
tional PCR fragments, providing no evidence that the shorter 
product could be the result of normal alternative splicing. 
Lane 5: Water control. Lane 6: 100 bp ladder.
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The five novel SDHB mutations described here further
underline the importance of germline mutations of this
gene in cases of paraganglioma and pheochromocytoma.
The striking variability in the penetrance and phenotype
of SDHB mutations in several the families described illus-
trates the difficulty in ascertaining the family history of
patients. Similarly, McDonnell et al [11] recently
described a remarkable pedigree in which a single case, a
young boy, led to the detection of a further 17 SDHB
mutation carriers, 4 of whom were phenotypically
affected.
The true contribution of heredity in the incidence of par-
aganglioma/pheochromocytoma is currently undergoing
a reappraisal [32]. The traditional view of pheochromocy-
toma, in which 10% of tumors were thought to be hered-
itary [33] has now been superceded by the realization that
germline mutations underlie at least 25% of cases [12].
Much of this increase is attributable to the recent availa-
bility of genetic testing of SDH genes. The full extent of the
role of germline mutations may still have been underesti-
mated. When the incidence of clinically manifest pheo-
chromocytoma (1 in 500,000) [34-36] is compared to
that found in two autopsy studies (1 in 2000) [37,38], it
seems that only a minority of tumors are being detected
clinically. Even considering an ascertainment bias of the
autopsy studies due to unrecognized pheochromocy-
toma-related cause of death, the difference in prevalence
suggests that many pheochromocytoma patients without
or with mild symptoms do not seek medical help and thus
will not come to a clinician's attention.
This may have important implications for both the gen-
eral biology and genetics of these tumors. A full under-
standing of the biology of adrenal and extra-adrenal
paragangliomas in relation to paragangliomas of the par-
asympathetic system, both in regard to the spatial limita-
tions for undetected tumor growth in the head and neck
region compared to the abdomen, and the extent to which
adrenal and extra-adrenal paragangliomas produce cate-
cholamines, might eventually lead to some convergence
in the phenotypic description of these tumors.
A recent study of patients with SDHD-linked head and
neck paragangliomas [39] showed that both catecho-
lamine excess and extra-adrenal paragangliomas/pheo-
chromocytomas in this group are higher than previously
thought, suggesting that SDH related tumors show dis-
tinct [13] but still broadly overlapping phenotypes.
The patient carrying a SDHC mutation described in this
report joins the small number of individuals with SDHC
mutations reported to date, which include a family show-
ing five cases of non-chromaffin paraganglioma and car-
rying a mutation that ablates the start codon ATG,
(c.3G>A) [6]. A subsequent report described a sporadic
female patient presenting with catecholamine-secreting
carotid body tumor, showing metastasis to a lymph node.
A splice donor site mutation (IVS5+1G>A) was identified
in this patient, resulting in the skipping of exon 5 [40].
More recently Bauters et al [41] identified a missense
mutation (c.473T>C; Leu158Pro) in a case of carotid
body paraganglioma, and Baysal et al [42] described a
family with head and neck paraganglioma with an 8 kb
Alu-mediated SDHC deletion. The patient described in
this report, a 36-year-old male of Turkish origin, was diag-
nosed with a single carotid body tumor (3.5 cm diame-
ter), and no other complications.
The c.214C>T change in SDHC results in the substitution
of arginine for cysteine. Arginine 72 (equivalent residue in
E. coli: – Arg31) is situated in a highly conserved protein
motif (E. coli: aa27-SILHR-aa31, S. cerevisiae: aa43-SSLHR-
aa47, H. sapiens: aa68-SICHR-aa72) that constitutes the
quinone-binding site of the succinate-ubiquinone reduct-
ase (SQR) complex in E. coli, [43,44]. Mutants of E. coli
carrying a substitution of arginine 31 are unable to grow
aerobically on succinate as a carbon source. In addition,
mutation of the histidine adjacent to Arginine 47 caused
a marked reduction in the catalytic efficiency of quinone
reduction in S. cerevisiae [45].
Although relatively few SDHC mutations carriers are
known, totaling 15 individuals, including 4 with no other
known affected family members, all affected individuals
had head and neck paragangliomas, including one case of
a metastatic, catecholamine-secreting carotid body tumor.
Despite the small numbers the parallels with SDHD are
obvious, and not altogether surprising in the light of the
probable functional equivalence of these genes.
Conclusion
In this study we detected germline mutations of SDHB in
5% and of SDHC in 2.5% of sporadic head and neck par-
aganglioma cases. Including data from published studies,
a total of 5 mutations of SDHB (3.5%) and 1 of SDHC
(0.7%) have been reported in 141 cases. Together with
our previous study of SDHD mutations we have now
found 27 SDH germline mutations in 95 cases (28%) of
sporadic head and neck paraganglioma, the majority of
these being Dutch founder mutations of SDHD. These
data indicate that germline mutations of SDHB and
SDHC play a minor role in sporadic head and neck para-
ganglioma. In contrast, germline mutations of SDHB were
found in all cases of familial pheochromocytoma and/or
paraganglioma. The clinical data presented illustrates the
striking variability in phenotype related to SDHB muta-
tions, even within a single family.BMC Medical Genetics 2006, 7:1 http://www.biomedcentral.com/1471-2350/7/1
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The mutation of SDHC reported here is only the fifth to
be described, extending our knowledge of the phenotype
related to mutations of this gene
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